Non-invasive biomarker to identify subject at risk of preterm delivery
First Claim
Patent Images
1. A method for assessing the likelihood of preterm delivery for a pregnant woman with an intact amniotic membrane, the method comprising:
- receiving a cervical vaginal secretion sample collected from a pregnant woman, the cervical vaginal secretion sample being collected with an absorptive media and treated with a protease inhibitor to reduce proteolysis;
measuring lipocalin-type prostaglandin D2 synthase (L-PGDS) concentration from the cervical vaginal secretion sample;
andadministering to the pregnant woman, selectively in dependence on the measured lipocalin-type prostaglandin D2 synthase (L-PGDS) concentration of at least 1.8 μ
g/ml, an effective amount of a therapeutic composition to avoid or mitigate preterm delivery, comprising at least one compound selected from the group consisting of;
a prostaglandin DP1 receptor antagonist,a prostaglandin DP2 receptor antagonist, anda selective L-PGDS inhibitor.
2 Assignments
0 Petitions
Accused Products
Abstract
Methods for diagnosis to allow prediction of the likelihood of preterm birth based upon the concentration of lipocalin-type prostaglandin D2 synthase (L-PGDS) in cervical vaginal secretions. In addition, specific prostaglandin D2 receptor antagonists may represent novel tocolytic therapeutics.
-
Citations
19 Claims
-
1. A method for assessing the likelihood of preterm delivery for a pregnant woman with an intact amniotic membrane, the method comprising:
-
receiving a cervical vaginal secretion sample collected from a pregnant woman, the cervical vaginal secretion sample being collected with an absorptive media and treated with a protease inhibitor to reduce proteolysis; measuring lipocalin-type prostaglandin D2 synthase (L-PGDS) concentration from the cervical vaginal secretion sample; and administering to the pregnant woman, selectively in dependence on the measured lipocalin-type prostaglandin D2 synthase (L-PGDS) concentration of at least 1.8 μ
g/ml, an effective amount of a therapeutic composition to avoid or mitigate preterm delivery, comprising at least one compound selected from the group consisting of;a prostaglandin DP1 receptor antagonist, a prostaglandin DP2 receptor antagonist, and a selective L-PGDS inhibitor. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
-
Specification